Intrathecal antitetanus serum (horse) in the treatment of tetanus.
In a two-year study of 322 conservatively treated, consecutive cases of tetanus in a rural hospital (all over twelve months old), intrathecal administration of 200 units of antitetanus serum (A.T.S.) (horse) reduced the overall mortality of 4-5% (5/110) compared with 14-5% (16/111) in the control series. 200 units intrathecal A.T.S. (horse) gave better results than 1500 units A.T.S. (horse). The results with lumbar and cisternal administration did not differ. It is suggested that tetanus is a polysystemic condition requiring polysystemic therapy. A regimen in which intrathecal A.T.S. is given as an adjunct to low-dosage systemic A.T.S., high levels of systemic betamethasone and diazepam, and careful nursing gave results which compare favourably with those of centres with more elaborate equipment and specialised staff.
D000293:Adolescent; D000328:Adult; D000818:Animals; D002946:Cisterna Magna; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005069:Evaluation Studies as Topic; D005260:Female; D006736:Horses; D006801:Humans; D007194:India; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007278:Injections, Spinal; D008297:Male; D012423:Rural Health; D013129:Spinal Puncture; D013742:Tetanus / Q000401:mortality / Q000628:therapy*; D013743:Tetanus Antitoxin / Q000008:administration & dosage* / Q000627:therapeutic use
D013743:Tetanus Antitoxin